Navigation Links
DNA2.0 Expands European Presence By Opening UK Office: Experienced Life Sciences Executive, Dr. Michael Dyson, to Lead European Operations
Date:12/10/2008

cience businesses across Europe, and prior to joining DNA2.0 he was European Managing Director for Codon Devices. He has also held chief management positions at such life science companies as Sequenom, MicroCal and PerSeptive Biosystems.

About DNA2.0:
Founded in early 2003, DNA2.0 is the leading synthetic genomics company. It is the fastest provider of synthetic genes, based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 has provided genes to thousands of customers, for whom it has synthesized many millions of base pairs. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene synthesis process and new protein optimization technologies. The tools and applications brought to market by DNA2.0 are transforming biology into an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit www.DNA20.com.

###

Read the full story at http://www.prweb.com/releases/2008/12/prweb1731564.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
2. Rohm and Haas Expands in India
3. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
4. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
5. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
6. Specialty Blades, Inc. Expands Management Team With New VP Engineering
7. CRH Medical expands Las Vegas operations
8. US Med-Equip Expands Corporate Support Center
9. ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
10. Bipartisan Bill Expands Health Care Access for Small Businesses
11. ABR-Affinity BioReagents Expands 100% Quality Guarantee
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 1U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 2U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 3U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 4U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 5West to Present at Two Upcoming Investor Conferences 56960 1West to Present at Two Upcoming Investor Conferences 56960 2Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 1Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 2